The result showed concurrent depletion of CD8+ T cells markedly weakened ZCV@D‐Gel‐mediated tumor regression and compromised survival (Figure 3J), suggesting that ZCVCT26@D‐Gel might activate a CD8+ T cell immune response to exert 4T1 tumor killing. The gene discussed is CD8A; the disease is neoplasm.